Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.

Taiki HakozakiYukio HosomiAkihiro ShimizuRui KitadaiKie MirokujiYusuke Okuma

Published in: Journal of cancer research and clinical oncology (2020)

Polypharmacy is an independent prognostic factor in older patients with advanced NSCLC treated with ICI. Also, polypharmacy could be utilized as a simple indicator of patients' comorbidities and symptoms or as a predictive marker of unexpected hospitalizations during ICI treatment.

Keyphrases

prognostic factors
advanced non small cell lung cancer
epidermal growth factor receptor
newly diagnosed
small cell lung cancer
adverse drug
physical activity
end stage renal disease
emergency department
sleep quality
peritoneal dialysis
combination therapy
tyrosine kinase
drug induced